MindBio Therapeutics Corp. announced first doses have been administered in MindBio's Phase 2B randomised, double blind and placebo controlled clinical trial in patients with advanced stage cancer who are experiencing emotional distress. In a world first, this is a Phase 2B government approved take-home trial of a psychedelic medicine (MB22001), a titratable form of LSD, designed for safe dosing in the community.

MindBio now has two Phase 2 clinical trials underway: Phase 2A LSD-Microdosing (MB22001) in patients with Major Depressive Disorder, and; Phase 2B LSD-Microdosing (MB22001) in patients with late stage cancer patients. MindBio now has two phase 2 clinical trials underway: Phase2A LSD-Microdosing ("MB22001") in patients with Major Depressive disorder, and;; Phase 2B LSD- Microdosing (MB22001") in patients With late stage Cancer. MindBio Therapeutics and Chief Executive Officer and Co-founder Justin Hanka have been nominated in a number of profile industry awards.

MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.